钆塞酸增强高时间分辨率肝动脉期成像联合视图共享技术:对LI-RADS分类的影响
研究纳入47例肝细胞癌患者共108个结节,评估视图共享多肝动脉期(mHAP)成像对富血供肝细胞癌LI-RADS分类的价值。基于单动脉期,24个(22.2%)结节归为LR-3;mHAP上73.1%的结节可见晕状强化,其中75%的LR-3结节因晕状强化而升级。视图共享mHAP可行且不损害图像质量,有助于提高钆塞酸增强MR对富血供肝细胞癌的诊断信心。
要点
- 视图共享mHAP可在不损害图像质量的前提下提高富血供肝细胞癌的诊断信心。
- 单动脉期上22.2%(24/108)的肝细胞癌归为LR-3,mHAP上75%的LR-3结节可见晕状强化并因此升级。
- mHAP上73.1%的肝细胞癌可见晕状强化,与血管造影CT相比晕状强化出现频率无显著差异(P=0.11)。
核心结论
- 视图共享mHAP可行且不损害图像质量,有助于提高钆塞酸增强MR对富血供肝细胞癌的诊断信心。
研究设计与样本
- 连续纳入47例肝细胞癌患者,在血管造影CT和碘油CT前接受钆塞酸增强MR检查,以血管造影CT和碘油CT确认的108个肝细胞癌结节(大小5-88mm,平均18.2mm)为参考标准。
关键影像表现/征象
- 基于单动脉期,24个肝细胞癌(22.2%,大小6-19mm,平均12.3mm)归为LR-3。
- 包膜表现(25.9%)和廓清(57.4%)最常在延迟期(2分钟)观察到。
- mHAP上73.1%的肝细胞癌可见晕状强化。
- 24个LR-3肝细胞癌中,75%在mHAP上可见晕状强化并因此升级分类。
- 所有病例图像质量评为良好或优秀。
诊断标准与关键数值
- 基于单动脉期,24个(22.2%)肝细胞癌归为LR-3。
- mHAP上75%的LR-3肝细胞癌因晕状强化而升级分类。
- mHAP与血管造影CT之间晕状强化出现频率无显著差异(P=0.11)。
临床应用与阅片要点
- 视图共享mHAP可在不损害图像质量的前提下提高富血供肝细胞癌的诊断信心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the value of view-sharing multi-hepatic arterial-phase (mHAP) imaging for diagnosis of hypervascular hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Forty-seven consecutive patients with HCC underwent gadoxetic acid-enhanced magnetic resonance (MR) imaging before angiographic and lipiodol CT. Hepatic arterial-phase images were obtained at 5 consecutive phases with shared central k-space of 25%, followed by portal venous, late (2 and 3min), and hepatobiliary phase imaging. One-hundred-eight HCC nodules (size: 5-88mm, mean size: 18.2mm) confirmed on angiographic CT and lipiodol CT were evaluated for LI-RADS category and compared with single arterial-phase and mHAP findings regarding wash out, capsule, corona enhancement, and image quality.
RESULTS: Twenty-four HCCs (22.2%) (size: 6-19mm, mean size: 12.3mm) were categorized as LR-3 based on the single arterial-phase. Capsule appearance (25.9%) and washout (57.4%) were most frequently observed in late phase (2min). Corona enhancement was observed in 73.1% of all HCCs on mHAP. For the 24 HCCs of LR-3, corona enhancement was observed in 75% on mHAP and contributed to upgrade category. No significant difference was found in the frequency of corona enhancement between mHAP and angiographic CT (P=0.11). Image quality was valued as good or excellent in all cases.
CONCLUSION: View-sharing mHAP was feasible without compromising image quality and contributed to the improvement in diagnostic confidence for hypervascular HCC in gadoxetic acid-enhance MR imaging.
引用
- Goshima S, Noda Y, Kajita K, et al. Gadoxetic acid-enhanced high temporal-resolution hepatic arterial-phase imaging with view-sharing technique: Impact on the LI-RADS category. Eur J Radiol. 2017. PMID: 28709718. doi:10.1016/j.ejrad.2017.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。